Purpose: To determine the dose-limiting toxicities (DLTs) and the maximum tolerated dose (MTD) of oral topotecan administered weekly in patients with relapsed small cell lung cancer (SCLC).
Patients And Methods: Patients were treated with oral topotecan on days 1, 8, and 15, every 28 days. The dose was escalated by 0.5 mg/m² increments from the starting dose of 3 mg/m² until the MTD was reached. DLTs were defined as grade 4 neutropenia, febrile neutropenia, grade 4 thrombocytopenia, non-hematologic toxicity ≥grade 3, any toxicity precluding the treatment on days 8 or 15 of the first cycle, or delay of the second cycle for more than 7 days.
Results: Eighteen patients were enrolled. Thirteen patients received oral topotecan as second-line and five as third- or further-line treatment. The DLT level was reached at 4.5 mg/m², and the MTD was determined to be 4 mg/m². DLTs consisted of grade 2/3 neutropenia and grade 2 thrombocytopenia precluding treatment on day 15 of the first cycle or on day 1 of the second cycle. The most frequent toxicities were grade 2-3 neutropenia (27.8 % of patients), grade 2-3 anemia (33.3 %), grade 2 thrombocytopenia (16.7 %), and grade 2-3 fatigue (44.4 %). The response rate was 11.1 %, the median progression-free survival 2.3 months, and the median overall survival 5.1 months.
Conclusion: The recommended phase II dose of weekly oral topotecan in pretreated patients with SCLC is 4 mg/m² on days 1, 8, and 15 every 28 days.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/s00280-013-2167-0 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Myeloprotection effects of trilaciclib in Chinese patients with extensive stage small cell lung cancer (ES-SCLC) receiving chemotherapy-a real-world study.
J Thorac Dis
November 2024
State Key Laboratory of Neurology and Oncology Drug Development, Hainan Simcere Zaiming Pharmaceutical Co., Ltd., Haikou, China.
Background: Trilaciclib, an intravenous short acting cyclin-dependent kinase 4/6 inhibitor, has been approved for the prevention of chemotherapy-induced myelosuppression (CIM) in patients with extensive stage small cell lung cancer (ES-SCLC) receiving platinum/etoposide (EP) or topotecan (TPT)-based therapy in United States (US) since February 2021. Trilaciclib use received the priority review and approval in a real-world setting in China. This study thus aimed to collect real-world data and evaluate the protective effect of trilaciclib on CIM in Chinese patients with ES-SCLC.
View Article and Find Full Text PDFIs Intravenous and Oral Topotecan in Small-Cell Lung Cancer Truly Equal? A Case Report.
Case Rep Oncol
October 2024
Department of Pulmonology, Sint-Trudo Hospital, Sint-Truiden, Belgium.
Article Synopsis
- Topotecan is the standard treatment for relapsed small-cell lung cancer (SCLC), with both oral and intravenous forms being equally effective, but oral treatment has fewer side effects.
- A case study presented a patient with stable disease after using oral topotecan; however, when switched to intravenous topotecan due to supply issues, the patient experienced significant disease regression after one dose.
- This report highlights the first known instance of intravenous topotecan showing a better response than oral topotecan, with no clear reasons found for this difference.
Expert consensus: Profiling and management of advanced or metastatic epithelial ovarian cancer.
Rev Colomb Obstet Ginecol
June 2024
Instituto Nacional de Cancerología, Bogotá, Colombia.
Introduction and objective: The approach to patients with advanced or metastatic high-grade epithelial ovarian cancer (EOC) has evolved over time with the advent of new therapies and multimodal strategies. The objective of this consensus of experts is to generate national recommendations for the profiling and management of advanced or metastatic high-grade OEC, defined as stages III and IV of the “The International Federation of Gynecology and Obstetrics (FIGO) classification at the time of diagnosis to base on the literature review that included international evidence-based clinical practice guidelines (CPG). Material and methods: Eleven panelists (oncologists and gynecological oncologists) answered 8 questions about the profiling and management of advanced or metastatic ovarian epithelial carcinoma.
View Article and Find Full Text PDFChallenges and future perspectives for the use of temozolomide in the treatment of SCLC.
Cancer Treat Rev
September 2024
Medical Oncology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, 40138 Bologna, Italy; Department of Medical and Surgical Sciences (DIMEC), Alma Mater Studiorum, University of Bologna, 40126 Bologna, Italy. Electronic address:
Small-cell lung cancer (SCLC), accounting for 10-20 % of all lung tumors, represents the most aggressive high-grade neuroendocrine carcinoma. Most patients are diagnosed with extensive-stage SCLC (ES-SCLC), with brian metastases identified in ∼ 80 % of cases during the disease cours, and the prognosis is dismal, with a 5-year survival rate of less than 5 %. Current available treatments in the second-line setting are limited, and topotecan has long been the only FDA-approved drug in relapsed or refractory ES-SCLC, until the recent approval of lurbinectedin, a selective inhibitor of RNA polymerase II.
View Article and Find Full Text PDFAssessment of the surface contamination of the primary packaging of oral antineoplastic drugs and secondary packaging of chemotherapy preparations at a Swiss hospital.
J Oncol Pharm Pract
May 2024
Institute of Pharmaceutical Sciences of Western Switzerland (ISPSO), School of Pharmaceutical Sciences, University of Geneva, CMU, Geneva, Switzerland.
Introduction: Due to the high toxicity of antineoplastic drugs, handling their packaging could lead to the chemical contamination of hospital environments and exposure risks to healthcare professionals and patients. This study aimed to assess the contamination of two main surfaces: the outer primary packaging of oral antineoplastic drug formulations ( = 36) available on the Swiss market and the surface of secondary packaging of injectable antineoplastic drug preparations ( = 60) produced by the pharmacy of a Swiss hospital and carriers used for transport ( = 5).
Methods: Samples were collected using a validated wipe sampling method.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!